Quest Diagnostics vs DaVita
DaVita is the larger business, with $13.64bn of revenue in fiscal 2025 against $11.04bn for Quest Diagnostics (1.2 times as much). Quest Diagnostics grew faster (11.8% against 6.5%). Quest Diagnostics kept more of each dollar of sales as profit: a net margin of 9.0% against 5.5%.
| Latest fiscal year | Quest DiagnosticsDGX, 2025 | DaVitaDVA, 2025 |
|---|---|---|
| Revenue | $11.04bn | $13.64bn |
| Revenue growth | 11.8% | 6.5% |
| Net income | $992m | $747m |
| Operating margin | — | 15.0% |
| Net margin | 9.0% | 5.5% |
| Return on equity | 14.2% | — |
| Free cash flow | $1.36bn | $1.31bn |
| Cash | $420m | $676m |
| Total debt | $5.67bn | $10.34bn |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | 1.3% | — |
| Share buybacks | $450m | $1.31bn |
| Employees | 57,000 | 78,000 |
| Market value | $27.47bn | $11.45bn |
| Price vs our value range | Within our value range | — |
| Moat score | 70 (Strong) | 62 (Moderate) |
| Insider trades, 12 months | 0 buys, 29 sales | 0 buys, 10 sales |